Diabetic Retinopathy Market by Type (Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy) and by Management (Vitrectomy, Anti-VEGF Therapy, Laser Surgery, and Intraocular Steroid Injection)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020– 2029

                                          
Abstract
                    
The report covers forecast and analysis for the diabetic retinopathy market on a global and regional level. The study provides historical data from 2015along with a forecast from 2018to 2024based on revenue (USD Billion). The study includes drivers and restraints for the diabetic retinopathy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the diabetic retinopathy market on a global and regional level.

In order to give the users of this report a comprehensive view on the diabetic retinopathy market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein Type segment is benchmarked based on their market size, growth rate, and general attractiveness.


The report provides company market share analysis in order to give a broader overview of the key players in the diabetic retinopathy market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new type launch, agreements, partnerships, collaborations & joint ventures, research& development, and regional expansion of major participants involved in the diabetic retinopathy market on a global and regional basis.

The study provides a decisive view on the diabetic retinopathy market by segmenting the market based on type, management, and region. The segments have been analyzed based on present and future trends and the market is estimated from 2018to 2024. Based on the type, diabetic retinopathy market has been segmented into non-proliferative diabetic retinopathy and proliferative diabetic retinopathy. Non-proliferative diabetic retinopathy segment holds the majority market share, due to the rising number of diabetic retinopathy patients and increasing awareness. The management segment includes vitrectomy, anti-VEGF therapy, laser surgery, and intraocular steroid injection. Anti-VEGF therapy segment holds the majority share of the management segment, due to its multiple benefits when compared to other therapies.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries including the U.S., Canada, Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes the demand for diabetic retinopathy based on individual segments and types in all regions and countries.

The report also includes detailed profiles of end-players, Regeneron Pharmaceuticals, Novartis, Allergan, Genentech, Bayer AG, Aerpio Pharmaceuticals, BCN Peptides, Ampio Pharmaceuticals, ThromboGenics, Alimera Sciences, and Kowa Company, among others.

This report segments the global diabetic retinopathy market as follows:

Global Diabetic Retinopathy Market: By Type

	Non-Proliferative Diabetic Retinopathy
	Proliferative Diabetic Retinopathy

Global Diabetic Retinopathy Market: By Management

	Vitrectomy
	Anti-VEGF Therapy
	Laser Surgery
	Intraocular Steroid Injection

Global Diabetic Retinopathy Market: By Region

	North America
	
		The U.S.
	
	
	Europe
	
		UK
		France
		Germany
	
	
	Asia Pacific
	
		China
		Japan
		India
	
	
	Latin America
	
		Brazil
	
	
	The Middle East and Africa